cifenline has been researched along with Cardiomyopathy, Hypertrophic in 30 studies
Cardiomyopathy, Hypertrophic: A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hypertrophic cardiomyopathy is a common inherited cardiovascular disease present in one in 500 of the general population." | 2.50 | [Perioperative management for patients with hypertrophic cardiomyopathy]. ( Omae, T, 2014) |
| "Hypertrophic cardiomyopathy is a common cardiac complication in mitochondrial disorders, and the morbidity rate in neonatal cases is up to 40%." | 1.72 | A Case of Infantile Mitochondrial Cardiomyopathy Treated with a Combination of Low-Dose Propranolol and Cibenzoline for Left Ventricular Outflow Tract Stenosis. ( Kishita, Y; Kono, Y; Miyauchi, A; Murayama, K; Okazaki, Y; Omika, N; Osaka, H; Sato, T; Shimozawa, H; Takeda, A; Yada, Y; Yamagata, T, 2022) |
| "Coronary hyperemia was induced by an intravenous infusion of adenosine triphosphate and CFVR was calculated as the ratio of hyperemic to basal mean coronary diastolic flow velocity." | 1.33 | Cibenzoline improves coronary flow velocity reserve in patients with hypertrophic obstructive cardiomyopathy. ( Daimon, M; Hasegawa, R; Kawata, T; Komuro, I; Sekine, T; Takazawa, K; Takei, Y; Tanaka, N; Teramoto, K; Yoshida, K, 2006) |
| "Hypertrophic obstructive cardiomyopathy was diagnosed." | 1.32 | [Beneficial effect of cibenzoline in a patient with hypertrophic obstructive cardiomyopathy complicated with idiopathic interstitial pneumonia]. ( Hamada, M; Hara, Y; Ogimoto, A; Ohtsuka, T; Saeki, H; Saito, M; Shigematsu, Y; Yokoyama, A, 2003) |
| "A 54-year-old woman had been treated for hypertrophic cardiomyopathy and paroxysmal atrial fibrillation since 1992." | 1.30 | Hypertrophic cardiomyopathy with mid-ventricular obstruction and splenic infarction associated with paroxysmal atrial fibrillation: a case report. ( Hamada, M; Hara, Y; Hashida, H; Hiasa, G; Hiwada, K; Ikeda, S; Kitami, Y; Matsumoto, Y; Ohtsuka, T; Shigematsu, Y; Tokuyasu, K, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (10.00) | 18.2507 |
| 2000's | 13 (43.33) | 29.6817 |
| 2010's | 11 (36.67) | 24.3611 |
| 2020's | 3 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hamada, M | 13 |
| Shigematsu, Y | 12 |
| Ikeda, S | 6 |
| Ohshima, K | 2 |
| Ogimoto, A | 8 |
| Shimozawa, H | 1 |
| Sato, T | 1 |
| Osaka, H | 1 |
| Takeda, A | 1 |
| Miyauchi, A | 1 |
| Omika, N | 1 |
| Yada, Y | 1 |
| Kono, Y | 1 |
| Murayama, K | 1 |
| Okazaki, Y | 1 |
| Kishita, Y | 1 |
| Yamagata, T | 1 |
| Shiohira, S | 1 |
| Kawabata, M | 1 |
| Goya, M | 1 |
| Maeda, S | 1 |
| Sasano, T | 1 |
| Hirao, K | 2 |
| Kojima, T | 1 |
| Imai, Y | 1 |
| Fujiu, K | 1 |
| Asada, K | 1 |
| Ando, J | 1 |
| Watanabe, M | 1 |
| Yamashita, H | 1 |
| Komuro, I | 2 |
| Omae, T | 1 |
| Nakamura, M | 1 |
| Kubota, N | 1 |
| Isobe, S | 1 |
| Ieda, M | 1 |
| Kohno, T | 1 |
| Nishiyama, T | 1 |
| Maekawa, Y | 1 |
| Tsuruta, H | 1 |
| Murata, M | 1 |
| Yashima, F | 1 |
| Yanagisawa, R | 1 |
| Tanaka, M | 1 |
| Inami, S | 1 |
| Nasuno, T | 1 |
| Haruyama, A | 1 |
| Sano, M | 1 |
| Hayashida, K | 1 |
| Fukuda, K | 1 |
| Mukai, Y | 1 |
| Wada, K | 2 |
| Fujimoto, M | 1 |
| Hosomi, K | 1 |
| Kuwahara, T | 2 |
| Takada, M | 1 |
| Kubo, T | 1 |
| Kitaoka, H | 1 |
| Terauchi, Y | 1 |
| Tamura, S | 1 |
| Okawa, M | 1 |
| Yamasaki, N | 1 |
| Yabe, T | 1 |
| Doi, YL | 1 |
| Ishikawa, T | 1 |
| Iwashima, S | 1 |
| Ohzeki, T | 1 |
| Okayama, H | 3 |
| Nagai, T | 1 |
| Ohtsuka, T | 8 |
| Suzuki, J | 4 |
| Inoue, K | 2 |
| Nishimura, K | 2 |
| Saito, M | 3 |
| Miki, T | 1 |
| Higaki, J | 3 |
| Nomura, T | 1 |
| Kojima, A | 1 |
| Urakabe, Y | 1 |
| Enomoto-Uemura, S | 1 |
| Nishikawa, S | 1 |
| Keira, N | 1 |
| Matsubara, H | 2 |
| Tatsumi, T | 2 |
| Kajimoto, K | 1 |
| Imai, T | 1 |
| Minami, Y | 1 |
| Kasanuki, H | 1 |
| Yoshii, T | 1 |
| Hiasa, G | 4 |
| Sumimoto, T | 1 |
| Inaba, S | 3 |
| Funada, J | 1 |
| Hara, Y | 7 |
| Saeki, H | 3 |
| Matsunaka, T | 1 |
| Hamada, H | 1 |
| Okura, T | 1 |
| Hiwada, K | 5 |
| Yokoyama, A | 1 |
| Inada, K | 1 |
| Komukai, K | 1 |
| Mori, C | 1 |
| Nagasawa, H | 1 |
| Shibata, T | 1 |
| Mochizuki, S | 1 |
| Konishi, C | 1 |
| Shiraishi, J | 1 |
| Muraguchi, N | 1 |
| Ohtsuki, K | 1 |
| Inoue, M | 1 |
| Azuma, A | 1 |
| Takahashi, K | 1 |
| Kogaki, S | 1 |
| Kurotobi, S | 1 |
| Nasuno, S | 1 |
| Ohta, M | 1 |
| Okabe, H | 1 |
| Sakai, N | 1 |
| Taniike, M | 1 |
| Ozono, K | 1 |
| Aono, J | 2 |
| Watanabe, K | 2 |
| Sekine, T | 1 |
| Daimon, M | 1 |
| Hasegawa, R | 1 |
| Teramoto, K | 1 |
| Kawata, T | 1 |
| Tanaka, N | 1 |
| Takei, Y | 1 |
| Takazawa, K | 1 |
| Yoshida, K | 1 |
| Kodama, K | 2 |
| Ochi, T | 1 |
| Iwata, T | 1 |
| Tokuyasu, K | 1 |
| Matsumoto, Y | 1 |
| Hashida, H | 1 |
| Kitami, Y | 1 |
| Sasayama, T | 1 |
| Horimoto, M | 1 |
| Takeda, T | 1 |
| Takenaka, T | 1 |
| Inoue, H | 1 |
| Igarashi, K | 1 |
| Akino, M | 1 |
| Kikuchi, K | 1 |
| Kondo, I | 2 |
| Mizushige, K | 2 |
| Nozaki, S | 2 |
| Iwado, Y | 2 |
| Ohmori, K | 1 |
| Matsuo, H | 2 |
| Suzuki, M | 1 |
| Masugata, H | 1 |
| Kohno, M | 1 |
1 review available for cifenline and Cardiomyopathy, Hypertrophic
| Article | Year |
|---|---|
[Perioperative management for patients with hypertrophic cardiomyopathy].
Topics: Adrenergic beta-Antagonists; Anesthesia; Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Echoc | 2014 |
5 trials available for cifenline and Cardiomyopathy, Hypertrophic
| Article | Year |
|---|---|
Pharmacogenetic interactions between Angiotensin-converting enzyme insertion/deletion polymorphism and response to cibenzoline in patients with hypertrophic obstructive cardiomyopathy.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; DNA; Echocardiography; F | 2010 |
Antiarrhythmic drug cibenzoline attenuates left ventricular pressure gradient and improves transmitral Doppler flow pattern in patients with hypertrophic obstructive cardiomyopathy caused by midventricular obstruction.
Topics: Aged; Anti-Arrhythmia Agents; Blood Flow Velocity; Blood Pressure; Cardiomyopathy, Hypertrophic; Ech | 2005 |
Effect of intravenous administration of cibenzoline on left ventricular diastolic pressures in patients with hypertrophic cardiomyopathy: its relationship to transmitral Doppler flow profiles.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Natriuretic Factor; Blood Pressure; Cardiomyopathy, Hypertrophi | 2007 |
Class Ia antiarrhythmic drug cibenzoline: a new approach to the medical treatment of hypertrophic obstructive cardiomyopathy.
Topics: Aged; Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Echocardiography; Humans; Imidazoles; Mi | 1997 |
Antiarrhythmic drug, cibenzoline, can directly improve the left ventricular diastolic function in patients with hypertrophic cardiomyopathy.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Blood Pressure; Cardiomyopathy, Hypertrophic; Echocardiography, | 2001 |
24 other studies available for cifenline and Cardiomyopathy, Hypertrophic
| Article | Year |
|---|---|
Impact of cibenzoline treatment on left ventricular remodelling and prognosis in hypertrophic obstructive cardiomyopathy.
Topics: Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Humans; Imidazoles; Prognosis; Ventricular Rem | 2021 |
A Case of Infantile Mitochondrial Cardiomyopathy Treated with a Combination of Low-Dose Propranolol and Cibenzoline for Left Ventricular Outflow Tract Stenosis.
Topics: Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Constriction, Pathologic; Humans; Imidazoles; | 2022 |
Exercise-induced ventricular tachycardia in a case with hypertrophic cardiomyopathy taking cibenzoline.
Topics: Adolescent; Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Cardiopulmonary Resuscitation; Exe | 2021 |
An elevated cibenzoline level interacted with cyclosporine caused ventricular tachyarrhythmia and high defibrillation threshold in hypertrophic cardiomyopathy.
Topics: Cardiomyopathy, Hypertrophic; Cyclosporine; Defibrillators, Implantable; Drug Interactions; Female; | 2013 |
Impact of chronic use of cibenzoline on left ventricular pressure gradient and left ventricular remodeling in patients with hypertrophic obstructive cardiomyopathy.
Topics: Aged; Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Echocardiography; Electrocardiography; F | 2016 |
Effective Cibenzoline Treatment in a Patient With Midventricular Obstruction After Transcatheter Aortic Valve Implantation.
Topics: Aged, 80 and over; Anti-Arrhythmia Agents; Aortic Valve Stenosis; Cardiac Catheterization; Cardiomyo | 2016 |
Long-term impact of therapeutic drug monitoring on the risk of hypoglycemia in HOCM patients on cibenzoline therapy
.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Case-Control Studies; Drug Monito | 2016 |
Hemolytic anemia in a patient with hypertrophic obstructive cardiomyopathy.
Topics: Aged; Anemia, Hemolytic; Anti-Arrhythmia Agents; Atenolol; Cardiomyopathy, Hypertrophic; Echocardiog | 2010 |
Effect of cibenzoline on biventricular pressure gradients in a pediatric patient with hypertrophic obstructive cardiomyopathy.
Topics: Anti-Arrhythmia Agents; Cardiac Catheterization; Cardiomyopathy, Hypertrophic; Child; Echocardiograp | 2010 |
Antiarrhythmic agent cibenzoline attenuates latent obstruction in the left ventricular outflow tract of hypertrophic cardiomyopathy.
Topics: Aged, 80 and over; Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Female; Humans; Imidazoles; | 2011 |
Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Disopyramide; Echocardiography, D | 2010 |
Myocardial fibrosis attenuates the effect of cibenzoline on left ventricular diastolic function in patients with hypertrophic cardiomyopathy.
Topics: Cardiomyopathy, Hypertrophic; Diastole; Female; Fibrosis; Humans; Imidazoles; Male; Middle Aged; Myo | 2011 |
Attenuation of biventricular pressure gradients by cibenzo-line in an 18-year-old patient with hypertrophic obstructive cardiomyopathy.
Topics: Adolescent; Anti-Arrhythmia Agents; Blood Pressure; Cardiomyopathy, Hypertrophic; Echocardiography; | 2002 |
[Beneficial effect of cibenzoline in a patient with hypertrophic obstructive cardiomyopathy complicated with idiopathic interstitial pneumonia].
Topics: Aged; Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Female; Humans; Imidazoles; Lung Disease | 2003 |
Cibenzoline therapy for mitral regurgitation in patients with HOCM.
Topics: Cardiomyopathy, Hypertrophic; Echocardiography, Doppler; Female; Follow-Up Studies; Humans; Imidazol | 2004 |
Mitral regurgitation disappearance after cibenzoline treatment in a patient with hypertrophic obstructive cardiomyopathy.
Topics: Cardiomyopathy, Hypertrophic; Dose-Response Relationship, Drug; Drug Administration Schedule; Echoca | 2004 |
Beneficial effect of cibenzoline on left ventricular pressure gradient with sigmoid septum.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Blood Pressure; Cardiomyopathy, Hypertrophic; Dyspn | 2004 |
A novel mutation in the PTPN11 gene in a patient with Noonan syndrome and rapidly progressive hypertrophic cardiomyopathy.
Topics: Cardiomyopathy, Hypertrophic; Cardiovascular Agents; Chromosomes, Human, Pair 12; Drug Therapy, Comb | 2005 |
Cibenzoline improves coronary flow velocity reserve in patients with hypertrophic obstructive cardiomyopathy.
Topics: Adenosine Triphosphate; Aged; Analysis of Variance; Anti-Arrhythmia Agents; Blood Flow Velocity; Car | 2006 |
An early systolic sound associated with midventricular obstruction in a patient with hypertrophic cardiomyopathy.
Topics: Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Echocardiography, Doppler; Female; Heart; Hear | 1998 |
Hypertrophic cardiomyopathy with mid-ventricular obstruction and splenic infarction associated with paroxysmal atrial fibrillation: a case report.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Echocardiography; Female; | 1999 |
[Efficacy of cibenzoline for chest oppression and ventricular arrhythmia during effort and alcohol consumption in a patient with hypertrophic obstructive cardiomyopathy: a case report].
Topics: Administration, Oral; Aged; Alcohol Drinking; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiomy | 2000 |
Effect of cibenzoline on regional left ventricular function in hypertrophic obstructive cardiomyopathy.
Topics: Acoustics; Aged; Analysis of Variance; Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Echocar | 2000 |
Effect of cibenzoline, a class ia antiarrhythmic agent, on left ventricular diastolic function in hypertrophic cardiomyopathy.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Bisoprolol; Blood Flow Velocity; Cardiomyopathy, | 2001 |